START Midwest

Summary

START Midwest is a medical facility located in Grand Rapids, Michigan. This center is recognized for care of Solid Tumors, Lung Cancer, Cancer, Colorectal Cancer, Pancreatic Cancer and other specialties. START Midwest is involved with conducting 113 clinical trials across 191 conditions. There are 6 research doctors associated with this hospital, such as Nehal Lakhani, MD, Manish Sharma, MD, Katie Robinson, MD, and Sreenivasa Chandana, M.D., Ph.D..

Top PIs

Clinical Trials running at START Midwest

Lung Cancer

Colorectal Cancer

Breast Cancer

Solid Tumors

Cancer

Pancreatic Cancer

Ovarian Cancer

Endometrial Cancer

Non-Small Cell Lung Cancer

Squamous Cell Carcinoma

AU-007

for Advanced Cancer

This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w). Once the recommended phase 2 dose (RP2D) of AU-007 plus aldesleukin was determined, (AU-007 Q2w plus a single loading dose of aldesleukin), AU-007 plus aldesleukin is also being administered with avelumab or nivolumab.

Recruiting

1 award

Phase 1 & 2

8 criteria

PRO1184

for Cancer

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

Recruiting

1 award

Phase 1 & 2

7 criteria

BDTX-4933

for Cancer

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced/metastatic non-small cell lung cancer (NSCLC), Gastrointestinal (GI) cancers, and other solid tumors harboring KRAS, HRAS, NRAS, BRAF, and/or CRAF (Rapidly Accelerated Fibrosarcoma (RAF1)) mutations or alterations. A dose optimization part in adults with NSCLC may follow the dose escalation phase if the sponsor, in consultation with the safety review committee, decides it is necessary to further characterize the optimal dose. However, the study may also proceed directly to the expansion phase. The study population for the Dose Expansion part of the study comprises adults with advanced/metastatic NSCLC with KRAS and/or BRAF mutations, and with Pancreatic Ductal AdenoCarcinoma (PDAC), ColoRectal Cancer (CRC), and Biliary Tract Cancer (BTC) with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations and alterations. All patients will self-administer S241656 orally in 28-day cycles until disease progression, toxicity, withdrawal of consent, or termination of the study.

Recruiting

1 award

Phase 1 & 2